Uganda: New Drug Reduces TB Treatment By 1 Year

14 September 2018

Kampala — Patients suffering from multi-drug tuberculosis will be on treatment for only nine months and not nearly two years as it has been, the Ministry of Health has said.

Dr Stavia Turyahabwe, the acting assistant commissioner in-charge of national tuberculosis and leprosy, said a combination of new drugs has made it possible for the latest development.

"We did research and found that it was possible to treat drug resistant TB in a shorter time than initially it was," Dr Turyahabwe said yesterday in Kampala at an event organised to raise awareness about TB.

"Now the treatment takes a shorter period and this will encourage more patients to finish their treatment than taking the drugs for two years," she added.


Reducing the treatment period will also make it cheaper to offer treatment for the disease. Treating resistant TB requires about Shs18m in 20 months per patient.

But the new treatment has a combination of seven drugs, which the patients will take for the first five months and then complete the last four months on four drugs. The cocktail of kanamycin, clofazimine, ethambutol, ethionamide, isoniazid, moxifloxacin and pyrazinamide are some of the combinations patients will be taking.

Uganda is one of the top 30 countries in the world with the highest multi-drug resistant TB and Kampala tops the districts with the highest prevalence. It is estimated that one in every 100 and 12 in every 100 previously treated TB patients have developed resistance to TB treatment.

See What Everyone is Watching

More From: Monitor

Don't Miss

AllAfrica publishes around 600 reports a day from more than 150 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.